UCB says that its two Phase III trials for their lupus drug epratuzumab failed. The developer said that neither of the two doses used in the identical, late-stage trials proved statistically superior to a placebo. The CD-22 targeting antibody was in-licensed from Immunomedics ($IMMU), which was hammered hard after the news hit. Morris Plains, NJ-based Immunomedics' shares were down 42% in early trading Tuesday. Release